Lower cost Asian JE vaccine in prospect as Inviragen licenses cell tech to Vietnam producer

The US vaccines firm Inviragen has started off the new year on the right foot by meeting one of the main goals for its cell cultured Japanese encephalitis (JE) vaccine: to partner the program with a local manufacturer in an endemic region.

The US vaccines firm Inviragen has started off the new year on the right foot by meeting one of the main goals for its cell cultured Japanese encephalitis (JE) vaccine: to partner the program with a local manufacturer in an endemic region.

A new agreement gives the state-owned Vietnamese vaccines producer VABIOTECH (The Company for Vaccine and Biological Production No 1) exclusive...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anti-infective

More from Therapeutic Category

Lilly Looks For Muscle-Sparing Candidates In Pact With Juvena

 
• By 

Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By 

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

BioNTech To Buy mRNA Rivals CureVac

 

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.